Tokyo Tape
Sign in
← Torii Pharmaceutical

Annual report

4551.TEDINET S100QGWM
Period2022-01-01 → 2022-12-31
Filed2023-03-28
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 89
MetricValuePeriodScopeSource row
Revenue¥48.9bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥47.0bn2021-01-01 → 2021-12-31StandaloneNet sales
Revenue¥41.7bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥43.0bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Revenue¥62.6bn2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Operating income¥5.5bn2022-01-01 → 2022-12-31StandaloneOperating income
Operating income¥4.7bn2021-01-01 → 2021-12-31StandaloneOperating income
Ordinary income¥5.5bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income¥4.8bn2021-01-01 → 2021-12-31StandaloneOrdinary income
Ordinary income¥5.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.7bn2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥5.1bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥5.7bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Profit before tax¥4.8bn2021-01-01 → 2021-12-31StandaloneIncome before income taxes
Net income¥3.9bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income¥3.4bn2021-01-01 → 2021-12-31StandaloneProfit loss
Net income¥3.5bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥27.4bn2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Net income¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Total assets¥133.7bnat 2022-12-31StandaloneAssets
Total assets¥130.8bnat 2021-12-31StandaloneAssets
Total assets¥126.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥139.9bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total assets¥103.3bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥14.5bnat 2022-12-31StandaloneLiabilities
Total liabilities¥13.8bnat 2021-12-31StandaloneLiabilities
Net assets / equity¥119.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥117.0bnat 2021-12-31StandaloneNet assets
Net assets / equity¥115.1bnat 2020-12-31dStandaloneNet assets
Net assets / equity¥113.1bnat 2019-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥87.1bnat 2018-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥9.2bnat 2022-12-31StandaloneCash and deposits
Cash and deposits¥4.0bnat 2021-12-31StandaloneCash and deposits
Cash & equivalents¥45.4bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥58.4bnat 2021-12-31StandaloneCash and cash equivalents
Cash & equivalents¥61.6bnat 2020-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥58.8bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥15.7bnat 2018-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥2.4bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥156m2021-01-01 → 2021-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥3.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥42.5bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥8.3bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥13.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥7.6bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥2.1bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥27.1bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥1.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥140.392022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥120.132021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥124.472020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥974.982019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥41.512018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥124.462020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1002022-01-01 → 2022-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥482021-01-01 → 2021-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥482020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482019-01-01 → 2019-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482018-01-01 → 2018-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,243.08at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,165.38at 2021-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,097.55at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,029.3at 2019-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,103.28at 2018-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio89.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.5%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio80.8%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE3.3%2022-01-01 → 2022-12-31StandaloneRate of return on equity (5-year summary)
ROE2.9%2021-01-01 → 2021-12-31StandaloneRate of return on equity (5-year summary)
ROE3.1%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
ROE27.3%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
ROE1.3%2018-01-01 → 2018-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued28,800,000at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees563at 2022-12-31StandaloneNumber of employees
Employees560at 2021-12-31StandaloneNumber of employees
Employees568at 2020-12-31dStandaloneNumber of employees
Employees660at 2019-12-31dStandaloneNumber of employees
Employees1,049at 2018-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 1
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2022-12-31563 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 987
ItemContextValueUnit
Filing date cover pageFilingDateInstant2023-03-28
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第131期(自　2022年１月１日　至　2022年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)鳥居薬品株式会社
Company name in english cover pageFilingDateInstantTORII PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　松田　剛一
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町三丁目４番１号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03-3231-6811（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)財務経理部長　　髙島　幸宏
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町三丁目４番１号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-3231-6811（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)財務経理部長　　髙島　幸宏
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00934
Fund codeFilingDateInstant－
Security codeFilingDateInstant45510
Filer name in japaneseFilingDateInstant
Original text (Japanese)鳥居薬品株式会社
Filer name in englishFilingDateInstantTORII PHARMACEUTICAL CO., LTD.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2022-01-01
Current period end dateFilingDateInstant2022-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2022-12-31
Previous fiscal year start dateFilingDateInstant2021-01-01
Comparative period end dateFilingDateInstant2021-12-31
Previous fiscal year end dateFilingDateInstant2021-12-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant－
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of reporting company (text)FilingDateInstantText · Plus
Company history (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Overview of affiliated entities (text)FilingDateInstantText · Plus
Information about employees (text)FilingDateInstantText · Plus
Business policy business environment issues to address etc (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Research and development activities (text)FilingDateInstantText · Plus
Overview of capital expenditures etc (text)FilingDateInstantText · Plus
Major facilities (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass